Optical coherence tomography to guide percutaneous coronary intervention of the left main coronary artery: the LEMON study.


Journal

EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology
ISSN: 1969-6213
Titre abrégé: EuroIntervention
Pays: France
ID NLM: 101251040

Informations de publication

Date de publication:
11 Jun 2021
Historique:
pubmed: 24 11 2020
medline: 16 6 2021
entrez: 23 11 2020
Statut: epublish

Résumé

Intravascular ultrasound (IVUS)-guided PCI improves the prognosis of left main stem (LMS) PCI and is currently recommended by international guidelines. Although OCT resolution is greater than that of IVUS, this tool is not yet recommended in LMS angioplasty due to the absence of data. This pilot study aimed to analyse the feasibility, safety and impact of OCT-guided LMS PCI. This prospective, multicentre trial investigated whether patients might benefit from OCT-guided PCI for mid/distal LMS according to a pre-specified protocol. The primary endpoint was procedural success defined as follows: residual angiographic stenosis <50% + TIMI 3 flow in all branches + adequate OCT stent expansion (LEMON criteria). Seventy patients were included in the final analysis (median age: 72 [64-81] years, 73% male). The OCT pre-specified protocol was applied in all patients. The primary endpoint was achieved in 86% of subjects. Adequate stent expansion was observed in 86%, significant edge dissection in 30% and residual significant strut malapposition in 24% of the cases. OCT guidance modified the operators' strategy in 26% of the patients. The rate of one-year survival free from major adverse clinical events was 98.6% (97.2-100). This pilot study is the first to report the feasibility and performance of OCT-guided LMS PCI according to a pre-specified protocol.

Sections du résumé

BACKGROUND BACKGROUND
Intravascular ultrasound (IVUS)-guided PCI improves the prognosis of left main stem (LMS) PCI and is currently recommended by international guidelines. Although OCT resolution is greater than that of IVUS, this tool is not yet recommended in LMS angioplasty due to the absence of data.
AIMS OBJECTIVE
This pilot study aimed to analyse the feasibility, safety and impact of OCT-guided LMS PCI.
METHODS METHODS
This prospective, multicentre trial investigated whether patients might benefit from OCT-guided PCI for mid/distal LMS according to a pre-specified protocol. The primary endpoint was procedural success defined as follows: residual angiographic stenosis <50% + TIMI 3 flow in all branches + adequate OCT stent expansion (LEMON criteria).
RESULTS RESULTS
Seventy patients were included in the final analysis (median age: 72 [64-81] years, 73% male). The OCT pre-specified protocol was applied in all patients. The primary endpoint was achieved in 86% of subjects. Adequate stent expansion was observed in 86%, significant edge dissection in 30% and residual significant strut malapposition in 24% of the cases. OCT guidance modified the operators' strategy in 26% of the patients. The rate of one-year survival free from major adverse clinical events was 98.6% (97.2-100).
CONCLUSIONS CONCLUSIONS
This pilot study is the first to report the feasibility and performance of OCT-guided LMS PCI according to a pre-specified protocol.

Identifiants

pubmed: 33226003
pii: EIJ-D-20-01121
doi: 10.4244/EIJ-D-20-01121
pmc: PMC9724912
pii:
doi:

Types de publication

Journal Article Multicenter Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

e124-e131

Références

Am Heart J. 2018 Nov;205:97-109
pubmed: 30205242
PLoS One. 2017 Jun 22;12(6):e0179756
pubmed: 28640875
JACC Cardiovasc Imaging. 2015 Nov;8(11):1297-305
pubmed: 26563859
Circulation. 2016 Sep 27;134(13):906-17
pubmed: 27573032
Eur Heart J. 2015 Dec 14;36(47):3346-55
pubmed: 26242713
JACC Cardiovasc Interv. 2013 Oct;6(10):1035-45
pubmed: 24156964
Catheter Cardiovasc Interv. 2020 Oct 1;96(4):755-761
pubmed: 31631525
EuroIntervention. 2020 Jun 25;16(3):210-217
pubmed: 32011286
Int J Cardiol. 2017 Dec 1;248:108-113
pubmed: 28709701
Catheter Cardiovasc Interv. 2013 Sep 1;82(3):E173-83
pubmed: 23359350
Eur Heart J. 2018 Sep 14;39(35):3281-3300
pubmed: 29790954
EuroIntervention. 2018 May 20;14(1):112-120
pubmed: 29786539
Eur Heart J. 2019 Jan 7;40(2):87-165
pubmed: 30165437
N Engl J Med. 2016 Dec 8;375(23):2223-2235
pubmed: 27797291
EuroIntervention. 2015 Jan;10(9):e1-8
pubmed: 25599698
EuroIntervention. 2018 Feb 02;13(15):e1785-e1793
pubmed: 29131806
EuroIntervention. 2019 Feb 08;14(15):e1568-e1577
pubmed: 30479307
Circ Cardiovasc Interv. 2009 Jun;2(3):167-77
pubmed: 20031713
EuroIntervention. 2021 Jun 11;17(2):e132-e139
pubmed: 32392171
Lancet. 2016 Nov 26;388(10060):2618-2628
pubmed: 27806900
JACC Cardiovasc Interv. 2014 Mar;7(3):244-54
pubmed: 24650399

Auteurs

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH